MiMARK raises €4.2M seed to replace painful women's health biopsies
What's the deal? Barcelona-based MiMARK DiagnosticsDealroom has a profile for this one. Try Dealroom → has raised a €4.2 million ($4.9 million) seed round to commercialise non-invasive tests for endometrial cancer and endometriosis. The company, which spun out of the Vall d'Hebron Institute of ResearchDealroom has a profile for this one. Try Dealroom → in 2021, closed the round in two stages.
Who backed it? Clave CapitalDealroom has a profile for this one. Try Dealroom →, Nara CapitalDealroom has a profile for this one. Try Dealroom →, Namarel VenturesDealroom has a profile for this one. Try Dealroom →, and WA4STEAMDealroom has a profile for this one. Try Dealroom → contributed €1 million in May 2023. A second tranche in November came from CDTI InnvierteDealroom has a profile for this one. Try Dealroom → — a Spanish government co-investment vehicle that put in €270,000 — plus InvereadyDealroom has a profile for this one. Try Dealroom → and Canterbury ScientificDealroom has a profile for this one. Try Dealroom →.
Why it stands out: The round ranks in the 97th percentile among all-time seed deals in Spain's health sector, based on a sample of 586 rounds. MiMARKDealroom has a profile for this one. Try Dealroom → had already secured €4 million in non-dilutive funding before the seed: €1.5 million from EIT HealthDealroom has a profile for this one. Try Dealroom →'s Wild Card program in 2020 and €2.5 million from the European Innovation Council Accelerator in June 2023.
What MiMARK is building: Its lead product, GyLDEC, analyses proteins in uterine fluid collected through a minimally invasive pipelle device. It targets post-menopausal women with abnormal uterine bleeding, who are typically referred for diagnostic biopsies. The test aims to spare some patients from more invasive procedures.
For endometriosis, MiMARK is developing GyLDEndo, which uses a cervical swab and promises results within 48 hours. The test completed proof-of-concept testing on 200 cervical swabs, though the company has not disclosed peer-reviewed validation data.
What's the endgame? "Thanks to this funding we will advance on bringing our first product to the market; an In Vitro Diagnostic for Endometrial Cancer," said chief executive officer and co-founder Marina Rigau. The company declined to share its valuation and is now raising an €8 million round to scale the endometrial cancer diagnostic and expand.
What could go wrong? The endometriosis diagnostic faces a crowded field. UK regulators began endorsing non-invasive tests in 2026 after decades in which the condition required laparoscopic surgery to confirm — and diagnosis times there have averaged eight to ten years.
The signal: Investors are backing startups that replace painful, invasive gynaecological procedures with simpler diagnostics, an area long overlooked in women's health. MiMARK's outsized seed shows how public grants and private capital are combining to move these tests from lab to market.
Image credit: Generated with Gemini
